|
04 Mar 2021 |
Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
|
|
03 Mar 2021 |
FDA Approves Investigational New Drug (IND) for Neuroendocrine Tumors from Molecular Targeting Technologies, Inc.
|
|
01 Mar 2021 |
Applied Molecular Transport Expands Clinical Pipeline and Announces First Subject Dosed in Phase 1a Trial of Oral AMT-126
|
|
01 Mar 2021 |
LFB Announces that the European Medicines Agency (EMA) Has Accepted for Filing the Marketing Authorization Application for eptacog beta (activated), a Recombinant Coagulation Factor VIIa
|
|
01 Mar 2021 |
Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
|
|
28 Feb 2021 |
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
|
|
25 Feb 2021 |
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
|
|
23 Feb 2021 |
NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
|
|
23 Feb 2021 |
Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity
|
|
17 Feb 2021 |
Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
|
|
17 Feb 2021 |
Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
|
|
16 Feb 2021 |
Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™
|
|
16 Feb 2021 |
ReAlta Life Sciences Doses First Subject in Phase 1 Healthy Volunteers Study of RLS-0071
|
|
15 Feb 2021 |
Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart
|
|
12 Feb 2021 |
Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
|
|
12 Feb 2021 |
Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
|
|
10 Feb 2021 |
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
|
|
10 Feb 2021 |
BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
|
|
10 Feb 2021 |
Affibody and Inmagene announce IND Clearance for Izokibep (ABY-035) for the treatment of Ankylosing Spondylitis
|
|
09 Feb 2021 |
Brooklyn ImmunoTherapeutics Announces Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer
|
|
08 Feb 2021 |
Entera Bio Initiates New Research Program For Oral GLP-2
|
|
08 Feb 2021 |
Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center
|
|
04 Feb 2021 |
Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro
|
|
04 Feb 2021 |
Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
|
|
03 Feb 2021 |
VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome
|
